Abstract 1
The risk of transmission of ruminant transmissible spongiform encephalopathy (TSE) to 2 humans was thought to be low due to the lack of association between sheep scrapie and 3 incidence of human TSE. However a single TSE agent strain has been shown to cause 4 both bovine spongiform encephalopathy (BSE) and human vCJD, indicating that some 5 ruminant TSEs may be transmissible to humans. While the transmission of cattle BSE to 6 humans in transgenic mouse models has been inefficient, indicating the presence of a 7 significant transmission barrier between cattle and humans, BSE has been transmitted to a 8 number of other species. Here we aimed to further investigate the human transmission 9 barrier following passage of BSE in a sheep. Following inoculation with cattle BSE, gene 10 targeted transgenic mice expressing human PrP showed no clinical or pathological signs 11 of TSE disease. However following inoculation with an isolate of BSE that had been 12 passaged through a sheep, TSE associated vacuolation and proteinase-K resistant PrP 13 deposition were observed in mice homozygous for the codon 129-methionine PRNP gene. 14 This observation may be due to higher titres of the BSE agent in sheep, or an increased 15 susceptibility of humans to BSE prions following passage through a sheep. However 16 these data confirm that, contrary to previous predictions, it is possible that a sheep prion 17 may be transmissible to humans and that BSE from other species may be a public health 18 risk. 19
Introduction. 1
The transmissible spongiform encephalopathies (TSEs) are a group of fatal infectious 2 neurodegenerative diseases that include scrapie in sheep, bovine spongiform 3 encephalopathy (BSE) in cattle, and Creutzfeldt-Jakob disease (CJD) in humans. TSEs 4 are characterised by the accumulation in the brain of PrP Sc , which is a conformational 5 variant of the normal cellular host prion protein (PrP C ). The abnormal form of the protein 6 is protease resistant, detergent insoluble and aggregates in diffuse or amyloid deposits in 7 the central nervous system (CNS) and lymphoreticular system of infected animals. TSEs 8 are infectious diseases, and can be transmitted between animals of the same and different 9 species by a number of routes including oral, environmental, or iatrogenic exposure. The 10 host range is a specific characteristic of each strain, but TSE agents usually transmit more 11 readily within rather than between species. Low transmission rates are often observed 12 upon transmission to a new species, but on further passage in the new species increased 13 transmission rates and shorter incubation times are usually observed. This effect is 14 referred to as the species barrier. The ability of individual TSE agents to cross a species 15 barrier can be examined experimentally by direct inoculation of different species, or 16 modelled in transgenic mice expressing PrP sequences from these species. Modelling 17 species barriers in mice is particularly important when assessing the risks of infection in 18 humans. Such experiments can assess risk posed by different TSE agents, and also the 19 potential for mutation and adaptation of the agent to the new species. These experiments 20 can highlight changes that may result in the emergence of a new agent strain with a much 21 wider or unknown host range. 22
One TSE agent which has shown the ability to transmit to several different species is BSE, 1 where infection has been observed in captive and domestic feline species, and exotic 2 ungulates (kudu & nyala) probably due to ingestion of contaminated feed (13). In 1996 a 3 new variant form of CJD (vCJD) was reported in humans which presented with unusual 4 pathology and an extremely young age range compared to other human TSEs (30). Strain 5 typing experiments demonstrated that vCJD was caused by the same agent strain as BSE 6 (9, 23), indicating that exposure to contaminated foods may have also resulted in 7 transmission of BSE to humans. Humans had previously been thought to be at low risk 8 from contracting ruminant TSEs, as sheep scrapie has been endemic in many countries 9 for hundreds of years without any related foci of human TSE. However the link between 10 BSE and vCJD proved that ruminant TSEs are a public health risk, and that new ruminant 11
TSEs may potentially be transmissible to humans. 12
13
During the BSE epidemic, sheep were undoubtedly exposed to the BSE agent, however 14 no cases of BSE in sheep have been documented in the field. Sheep can however be 15 infected with BSE via oral, intravenous, and intracerebral routes (17, 18) , producing 16 clinical TSE with incubation periods ranging from months to years (depending on the PrP 17 genotype of the sheep), proving that this species is susceptible to infection with the BSE 18 agent. It is possible that low level BSE infection did exist in sheep during the height of 19 the BSE epidemic, however it is unknown whether this could have been masked by co-20 infection with scrapie. BSE has however been documented in goats (14, 25) , providing 21 evidence that infection of small ruminants in the field has occurred. Whether the 22 presence of BSE infection in sheep and goats would represent a risk to humans is 23 currently unclear. No previous association between sheep scrapie and human TSE has 1 been documented. This may be due to incompatibility between sheep and human PrP, or 2 the inability of natural scrapie strains to replicate efficiently in a human host. If the agent 3 strain is ultimately responsible for this lack of transmission rather than a sheep/human 4 barrier, it is possible that BSE in other ruminant species may pose a risk to humans. 5 6 In order to address the transmissibility of cattle and sheep derived BSE to humans we 7 performed inoculations of BSE infected sheep brain into a panel of gene targeted 8 transgenic mice expressing human PrP under the same spatial and temporal controls as 9 wild type PrP (4) . Three lines of transgenic mice were used representing the genetic 10 diversity in the human population due to the PrP codon 129 methionine/valine 11 polymorphism; HuMM (40%), HuMV (50%) and HuVV (10%). This polymorphism is 12 known to affect human susceptibility to TSE, and to date all confirmed clinical cases of 13 vCJD have occurred in individuals who are methionine homozygous at PrP codon 129. 14 Although previous experiments showed no disease transmission from cattle BSE in any 15 of these human transgenic mouse lines (4), we show here that experimental sheep BSE 16 produced pathological evidence of disease transmission in ~70% of HuMM transgenic 17 mice, suggesting that sheep BSE may be a greater risk to humans than cattle BSE. 18
19

Materials and Methods 1
Transgenic Mice 2
Inbred gene targeted human PrP transgenic mice with the codon-129 methionine/valine 3 polymorphism have been described previously (4) . Transgenic lines homozygous for the 4 polymorphism were crossed to produce all three genotypes represented in the UK 5 population (designated HuMM, HuMV, and HuVV, respectively) as previously described 6 (4). Brain tissue from a group of uninoculated HuMM and HuVV mice that had 7 previously been allowed to age to over 700 days were utilised as controls in 8 immunohistochemical analyses. In addition a gene targeted bovine transgenic line 9 expressing bovine PrP with the 6-octapeptide repeat region (Bov6), and wild-type 10 129/Ola mice were used as control lines (4) . The Bov6 gene targeted transgenic line is 11 the same line described as "BovTg" in Bishop et al, 2006 (4) . Weybridge, UK) was generated and published previously (4) . The 129/Ola wild type 10 mice inoculated with cattle BSE described here were inoculated in the same manner with 11 the same BSE brainstem pool as part of this work, but were not included in the original 12 publication (4). 13
All mice were intracerebrally (i.c.) inoculated with 0.02ml of inoculum per mouse into 14 the right mid-hemisphere. Following the inoculation, mice were monitored daily and 15 scored once a week for signs of clinical disease. Mice were culled at a pre-defined 16 clinical endpoint (12) , or due to welfare reasons, and brain tissue recovered at post 17 mortem. One half of the brain was fixed in formal saline, further trimmed to expose a 18 number of different regions of the brain (frontal cortex, cortex, hippocampus, thalamus, 19 cerebellum and brain stem) then wax embedded to allow 6µm sections to be cut for use in 20 pathological analysis of the tissue. The second half of each brain and the spleen (where 21 available) were snap frozen in liquid nitrogen for biochemical analysis. Each mouse was 22 genotyped post-mortem to confirm PrP genotype. All mouse experiments were reviewed 23 and approved by the Local Ethical Review Committee, and performed under license from 1 the UK Home Office in accordance with the UK Animals (Scientific Procedures) Act 2
3 4
Analysis of vacuolar pathology 5
Sections were cut (6µm) from each mouse brain and stained using haematoxylin and 6 eosin (H&E). Nine regions of the grey matter (dorsal medulla, cerebellar cortex, superior 7 colliculus, hypothalamus, thalamus, hippocampus, septum, cerebral cortex, and forebrain 8 cerebral cortex) and three regions of white matter (cerebellar white matter, midbrain 9 white matter and cerebral peduncle) were examined and scored on a scale of 0 (no 10 vacuolation) to 5 (severe vacuolation) for the presence and severity of vacuolation. Mean 11 vacuolation scores for each mouse group in each experiment were calculated and plotted 12 with standard error of mean (SEM) against scoring areas to produce a lesion profile (21). 13
14
Immunohistochemical analysis of PrP deposition in brain 15
To identify PrP deposits in the brain, two methods of immunohistochemical (IHC) 16 analysis were employed. (i) ABC kit (Vectastain); brain sections (6µm) were pre-treated 17 using hydrated autoclaving at 121 o C for 15 min and exposure to formic acid (95%) for 18 5min prior to incubation with 0.44µg/ml anti-PrP monoclonal antibody 6H4 (Prionics) at 19 room temperature overnight. Biotinylated secondary anti-mouse antibody (Jackson 20 Immuno Research Laboratories, UK) was added at 2.6µg/ml and incubated at room 21 temperature for 1h. PrP Sc was visualised by a reaction with hydrogen peroxidase-22 activated diaminobenzidine (DAB). (ii) When levels of PrP Sc detected using the ABC kit 23 were low or zero, the DAKO Catalysed Signal Amplification kit (CSA II (Vectastain)) 1 was used. IHC was performed using the same principals as in (i), but with an additional 2 streptavidin-biotin-peroxidase amplification step (see manufacturer's information). 3
Sections were pre-treated as above prior to incubation with 0.44µg/ml monoclonal 4 antibody 6H4 at room temperature overnight. Anti-mouse immunoglobulins, supplied 5 with the CSA II kit, were added and incubated for 60min at room temperature. PrP Sc 6 detection by a reaction with hydrogen peroxidase-activated DAB. 7 8
Immunohistochemical detection of glial activation 9
To detect astrocyte activation, brain sections (6µm) were incubated with 1.45µg/ml anti-10 glial fibrillary acidic protein (GFAP, Dako UK Ltd) antibody at room temperature for 1h. 11
To detect microglia activation, brain sections (6µm) were pre-treated using hydrated 12 microwaving for 10min prior to incubation with 0.05µg/ml anti-Iba1 antibody (Wako 13 Chemicals GmbH) at room temperature for 1h. For both primary antibodies, a 14 biotinylated secondary anti-rabbit antibody (Jackson Immuno Research Laboratories, 15 UK) was added at 2.6µg/ml and incubated at room temperature for 1h. Astrocytes and 16 microglia were visualised by a reaction with hydrogen peroxidase-activated DAB. 17
18
Detection of amyloid plaques by thioflavin fluorescence 19
Sections (6µm) were processed and exposed to 1% thioflavin-S (Sigma, UK) solution as 20 described previously (28). Viewed under a fluorescence microscope amyloid deposits 21 fluoresce bright green. 22
Identification of PrP Sc in spleen tissue 1
Spleen tissues that were available from HuMM transgenic mice inoculated with 2 experimental sheep BSE inoculum-2 were screened by the IDEXX HerdChek assay 3 following the manufacturers' guidelines. Buffer volumes for homogenisation were 4 adjusted to ensure that all homogenates were 30% (w/v) for consistency. 5 6
Identification of PrP Sc by immunoblot 7
Brain tissues from HuMM transgenic mice, Bov6 transgenic mice and wild type 129/Ola 8 mice inoculated with experimental sheep BSE inoculum-2 were prepared for analysis by 9 immunoblot. Samples from the experimental sheep BSE source brain and from isolates of 10 natural scrapie were also prepared as controls. Due to the focus of PrP deposition and the 11 amyloid nature of much of the disease associated PrP in HuMM transgenic mice, a 12 centrifugal concentration extraction procedure (including proteinase K digestion) was 13 performed as described previously (24) to maximise the possibility of identifying PrP-res. 14 Samples were loaded and run on 16% Tris-Glycine acrylamide gels (Novex, Invitrogen) 15 at varying concentrations (0.6mg -64mg brain equivalent) to allow comparison between 16 lanes, and immunoblotted onto PVDF membrane. To achieve a detectable signal, 17 approximately 64mg brain equivalent was loaded from HuMM brain tissue, compared to 18 0.88mg brain equivalent from experimental sheep BSE infected Bov6 controls. 19
Monoclonal antibodies 6H4 (0.1µg/ml) and 12B2 (0.2µg/ml) were used to detect PrP, and 20 bands were visualised using HRP labelled anti-mouse secondary antibody (Jackson 21
Immuno Research Laboratories, UK) and a chemiluminescence substrate (Roche) 22
Results. 1
BSE strain characteristics are retained following transmission in sheep. 2
For both experimental sheep BSE inoculum-1 and inoculum-2, 100% transmission rates 3 were observed in 129/Ola and Bov6 control mice. Experimental sheep BSE inoculum- 1 4 produced incubation times in 129/Ola and Bov6 mice of 474 ±22 days and 564 ±8 days 5 respectively ( Table 1) , similar to those observed in a previous experiment following 6 inoculation of these lines with a cattle BSE brain pool (4). Inoculum-2, prepared from the 7 same BSE infected sheep, gave incubation times of 403 ±17 days and 487 ±3 days in 8 129/Ola and Bov6 mice respectively (Table 1 ). In each line of mice, the lesion profiles of 9 cattle and sheep BSE were similar indicating no change in the targeting properties of BSE 10 following passage through sheep ( Figure 1 ). Lesion profiles of sheep BSE inoculum-1 11 and inoculum-2 were also similar, although the degree of vacuolation was slightly 12 reduced for inoculum-2. This may represent the shortened incubation times observed in 13 these mice. Although these shortened incubation times may reflect a higher level of agent vacuolar pathology in the brain. All other human transgenic mice showed no clinical 23 signs of TSE disease and no TSE associated vacuolar pathology (Table 1) . This agreed 1 with previous data generated following inoculation of these human transgenic mouse 2 lines with cattle BSE (4), indicating the presence of a significant transmission barrier to 3 the BSE agent in humans. However, in order to rule out the presence of subclinical 4 disease, the oldest mice were screened for abnormal PrP deposition by 5 immunohistochemistry (IHC) using the anti-PrP antibody 6H4. Of all animals screened, 6 one HuMM mouse which was culled due to old age (706 days post inoculation) showed a 7 small focus of PrP deposition in the thalamus ( (≈750 days) showed modest GFAP and Iba1 immunoreactivity in isolated cells with 21 slender processes ( Fig. 4a,e ). PrP amyloid deposits were not seen in these animals ( Fig.  22 4c, g). In contrast, astro-and micro-gliosis were observed in HuMM mice inoculated with 23 sheep BSE inoculum-2 in brain areas with abundant PrP amyloid deposition e.g., the 1 lateral geniculate nucleus (LGN) (Figure 4b, d, 
Peripheral accumulation of PrP Sc in spleen 5
The IDEXX HerdChek assay was used to analyse spleen tissue available from 17 of the 6 23 HuMM mice inoculated with experimental sheep BSE inoculum-2. Positive assay 7 readouts were obtained for 10 of the 17 spleens analysed ( Table 2 ). The detection of 8 abnormal PrP in spleen tissue by the IDEXX HerdChek assay did not correlate with PrP 9 deposition observed in the brain of the same animal. Of the 10 IDEXX positive samples, 10 three were from mice in which the brain was scored negative by IHC with anti PrP 11 antibody 6H4 (culled at 422 and 658 days post inoculation). In contrast, the three oldest 12 spleen samples available (623, 687 and 750 days post inoculation) were all negative, 13 despite moderate PrP deposition in the brain ( Table 2) . 14
15
Susceptibility of human transgenic mice to natural sheep scrapie. 16
Brain homogenate from two VRQ/VRQ sheep with clinically and pathologically 17 confirmed scrapie was used to inoculate the transgenic mouse panel. For both isolates, 18 the presence of clinical and pathological signs of TSE disease were observed only in 19 some control 129/Ola wild type mice with long incubation times (Table 1) , as has been 20 observed previously in C57 and RIII mice (8) . Clinical signs were recorded in several 21 other mice (2 x Bov6 mice, 8 x HuMV and 1 x HuVV mouse), but none of these animals 22 showed signs of TSE associated pathology. No clinical signs of disease were observed in 23 any remaining transgenic mice, and animals were either culled for intercurrent disease or 1 due to old age. No evidence of TSE associated vacuolar pathology or PrP deposition was 2 observed in the human or bovine PrP gene targeted transgenic lines following 3 pathological examination of brain tissue (data not shown). While transmission of BSE from cattle to humans via oral exposure has been proposed as 2 the origin of vCJD, the risk posed to humans from BSE infection in other species is 3 currently unknown. Sheep can be experimentally infected with BSE, and it has long been 4 a concern that sheep may have become infected during the BSE epidemic. Although no 5 evidence of such infection has been identified in the field, cases of BSE in goats have 6 been reported (14, 25) . Here we have shown that inoculation of experimental sheep BSE 7 into gene targeted HuMM transgenic mice resulted in the identification of TSE related 8 pathology (PrP deposition, vacuolation, and gliosis) in ~70% of the animals overall, and 9 100% of HuMM mice surviving over 600 days. PrP Sc was detected in brain tissue by 10 immunoblot, and in spleen tissue of several mice using the IDEXX HerdChek assay. 11
Some of the oldest HuMM mice (623-750 days post inoculation) that showed PrP 12 deposition in the brain did not have detectable PrP Sc in spleen. This variability is not 13 unusual, as extremely old mice that show PrP Sc in the brain often have no corresponding 14 deposition in the spleen. This is likely due to loss of germinal centres in the spleen caused 15 by aging (7) . No evidence of disease transmission was observed in HuMV or HuVV 16 mice, mirroring the prevalence of vCJD disease observed to date in the UK population. 17
Although the presence of disease pathology indicates agent replication and early phase 18 disease, we cannot predict whether these mice would have developed clinical disease if 19 lifespan had been extended, or if this represents a persistent sub-clinical state. Subpassage 20 of brain material from HuMM mice will be performed to confirm agent replication, and 21 assess adaptation and host range of the agent. 22
Our results cast new light on the existing data concerning BSE transmission to humans. 1
Since the identification of the link between BSE and vCJD, many studies have been 2 performed to demonstrate or model the transmission of BSE to humans using in vitro 3 conversion techniques or by inoculation of transgenic mice expressing human PrP. In 4 these transmission studies, cattle BSE has shown limited transmissibility to human PrP 5 transgenic mice (~0-30%), and considerable variation in susceptibility exists between 6 different transgenic lines with varying constructs and protein expression levels (1, 3, 4, 7 11 ). Highest levels of susceptibility to BSE in mice expressing human PrP with codon previously showed no incidence of disease following cattle BSE inoculation (4). These 15 observations have lead to the assumption that over-expression of PrP is essential to model 16 human disease susceptibility in mice, and that rodent models with wild type physiological 17 levels of PrP expression do not live long enough to display signs of disease as would be 18 seen in the longer lifespan human species. It is therefore significant that the inoculation of 19 experimental sheep BSE described here has resulted in the identification of TSE related 20 pathology in the gene targeted human PrP transgenic mice. Additionally, previously 21 published data has shown that short incubation times can be achieved in HuMM and 22
HuVV gene targeted mice (5). Our data show clearly that gene targeted transgenic lines 23 are useful in the study of cross species susceptibility, and that such susceptibility depends 1 on the agent/host combination, rather than the lifespan of a mouse. The inclusion of data 2 obtained in both overexpressing and gene targeted transgenic mice may therefore inform 3 more accurately on the assessment of the true zoonotic potential of a particular TSE 4 isolate. seen previously with cattle BSE inoculations in these mice. Whether this is simply due to 19 agent infectivity titre or a more subtle change in agent characteristics is the subject of 20 further analysis in our laboratory. 21
22
Although sheep can be experimentally infected with BSE by oral, intravenous or 1 intracerebral exposure (18) , no cases of sheep BSE have been reported in the field. The 2 possible increased risk of disease transmission identified in these studies is thus not of 3 major concern to the public at present. Natural BSE infection has however been identified 4 in goats (14, 25) , indicating that small ruminants have been exposed to sources of 5 contamination. We cannot rule out the possibility that sheep may have been infected with 6 BSE during the height of the BSE epidemic, as these animals were undoubtedly exposed 7 to similar feed sources (although with different levels of exposure compared to cattle). 8
Such infection may have been limited and/or localised, and resolved very quickly. BSE in 9 small ruminants may however represent an increased risk to humans due the wider 10 distribution of BSE infectivity identified in peripheral sheep tissues (2, 17, 19, 29 ) 11 compared to BSE in cattle which is mainly restricted to the CNS (10). While TSEs 12 remain in the environment and continue to infect animals (even at low prevalence) there 13 remains the potential for cross-species transmission and the emergence of TSE isolates 14 with altered strain properties, or host ranges. Our data therefore emphasise the need for 15 continued surveillance to identify, monitor and characterise any new emerging TSE 16 agents that are identified in ruminants, and assess the potential risks posed to other 17 species. Brain homogenates prepared from four individual sheep infected with BSE were inoculated separately into groups of RIII mice. Animals were monitored for signs of TSE disease, and culled at a defined clinical endpoint or due to intercurrent illness. The data show the variability that can be observed on primary inoculation of mice with experimental sheep BSE. Incidence of disease ranged from 78% to 100%, with incubation times ranging from 350 days to 607 days.
These observations are not uncommon in primary transmission studies.
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